RPL6P31: A Ribosomal Protein L6 Pseudogene as a Drug Target and Biomarker

Target Name: RPL6P31

NCBI ID: G441907

RPL6P31

Other Name(s): Ribosomal protein L6 pseudogene | ribosomal protein L6 pseudogene 31 | LOC441907

RPL6P31: A Ribosomal Protein L6 Pseudogene as a Drug Target and Biomarker

Ribosomal protein (RPN) L6 (RPL6) is a key regulator of protein synthesis in eukaryotic cells, responsible for ensuring the accurate assembly of various proteins into functional mature products. The protein encoded by the RPL6 gene is highly conserved across different species, and its structure and function have been well-studied. In this article, we will explore the RPL6 gene, its function, and its potential as a drug target and biomarker.

Structure and Function

The RPL6 gene is a member of the large Ribosomal Protein (RPN) family, which includes 21 different genes responsible for the synthesis of various RPNs. These genes are involved in the regulation of protein synthesis in eukaryotic cells, and the RPL6 gene is no exception.

The RPL6 gene encodes a protein with 124 amino acid residues, which is the length of the protein sequence. The protein has a molecular weight of approximately 18 kDa and a calculated pI of 5.95. The protein is expressed in most eukaryotic cells and is involved in regulating protein synthesis, specifically in the ribosome, which is the central organ for protein synthesis in eukaryotic cells.

The RPL6 gene is well characterized, and its function in protein synthesis has been extensively studied. It has been shown to play a crucial role in the regulation of protein synthesis in various cell types, including bacteria, yeast, and mammalian cells.

Drug Target Potential

The RPL6 gene has been identified as a potential drug target due to its involvement in the regulation of protein synthesis. Several studies have shown that inhibiting the activity of RPL6 can lead to a reduction in protein synthesis and cell growth, suggesting that targeting this gene may be an effective way to treat various diseases.

One of the compounds that has been shown to inhibit the activity of RPL6 is Q80, an inhibitor of the protein kinase CKP-4. CKP-4 is a key regulator of protein synthesis and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. By inhibiting CKP-4, Q80 has been shown to reduce the amount of protein synthesized by cancer cells, leading to a decrease in cell growth and a reduction in tumor size.

Another compound that has been shown to inhibit the activity of RPL6 is rapamycin, an inhibitor of the mTOR complex, which is involved in the regulation of protein synthesis and cell growth. Rapamycin has been shown to reduce the amount of protein synthesized by cancer cells, leading to a decrease in cell growth and a reduction in tumor size.

Biomarker Potential

The RPL6 gene has also been identified as a potential biomarker for various diseases, including cancer. The RPL6 gene has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have shown that RPL6 levels are often increased in cancer cells compared to healthy cells, making it a potential diagnostic biomarker for cancer.

Conclusion

In conclusion, the RPL6 gene has been shown to encode a protein involved in the regulation of protein synthesis in eukaryotic cells. Its function in protein synthesis has been extensively studied, and several compounds have been shown to inhibit its activity. Additionally, the RPL6 gene has been identified as a potential biomarker for various diseases, including cancer. Further research is needed to fully understand the role of RPL6 in protein synthesis and its potential as a drug target and biomarker.

Protein Name: Ribosomal Protein L6 Pseudogene 31

The "RPL6P31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL6P31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets